Who Exports Linagliptin from India — 118 Suppliers Behind a $3.9M Market
India's linagliptin export market is supplied by 118 active exporters who collectively shipped $3.9M across 1,375 shipments. BETA DRUGS LIMITED leads with a 65.1% market share, followed by GANPATI EXIM INC and SHREE SSD PHARMA PRIVATE LIMITED. The top 5 suppliers together control 76.3% of total export value, reflecting a concentrated market structure.
Top Linagliptin Exporters from India — Ranked by Export Value
BETA DRUGS LIMITED is the leading linagliptin exporter from India, holding a 65.1% share of the $3.9M market across 1,375 shipments from 118 exporters. The top 5 suppliers — BETA DRUGS LIMITED, GANPATI EXIM INC, SHREE SSD PHARMA PRIVATE LIMITED, BOEHRINGER INGELHEIM INDIA PRIVATE LIMITED, DELTA BIOPHARMA PRIVATE LIMITED — collectively control 76.3% of total export value, indicating a highly concentrated market. Individual shares are: BETA DRUGS LIMITED (65.1%), GANPATI EXIM INC (3.5%), SHREE SSD PHARMA PRIVATE LIMITED (3.3%), BOEHRINGER INGELHEIM INDIA PRIVATE LIMITED (2.3%), DELTA BIOPHARMA PRIVATE LIMITED (2.1%).
Top Linagliptin Exporters from India
Ranked by export value · 118 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | BETA DRUGS LIMITED LINAGLIPTIN TABLETS 5 MG | $2.5M | 1 | 65.1% |
| 2 | GANPATI EXIM INC PHARMACEUTICAL PRODUCT : | $135.6K | 1 | 3.5% |
| 3 | SHREE SSD PHARMA PRIVATE LIMITED PHARMACEUTICAL PRODUCT : | $127.6K | 1 | 3.3% |
| 4 | BOEHRINGER INGELHEIM INDIA PRIVATE LIMITED TRAJENTA 90/5MGPHARMA PRODUCT:GLYXAMBI 10/5MG NOS | $90.5K | 2 | 2.3% |
| 5 | DELTA BIOPHARMA PRIVATE LIMITED | $80.5K | 3 | 2.1% |
| 6 | LAWRENCE WALTER PHARMACEUTICAL PRODUCT :TRAJENTA 5MG SIZE-90 TABS/PACKSTRAJENTA 5MG SIZE-90 TABS/ | $69.5K | 3 | 1.8% |
| 7 | LOB INTERNATIONAL ,DIAZEN ,PACK:8 X 7 TAB. | $48.7K | 1 | 1.2% |
| 8 | CLAROID PHARMACEUTICALS PRIVATE LIMITED LINVESTA-EMP LINAGLIPTIN 5MG EMPAGLIFLOZIN 25 MGNOSLINVESTA-EMP LINAGLIPTIN 5 MG EMPAGLIFLOZIN 25 MG | $47.4K | 1 | 1.2% |
| 9 | KWALITY PHARMACEUTICALS LIMITED | $43.5K | 2 | 1.1% |
| 10 | 9M INDIA LIMITED LINAGLIPTIN TABLETS 5 MG | $43.1K | 1 | 1.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Linagliptin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| KWALITY PHARMACEUTICALS LIMITED | Not Listed | Yes | Yes | Not Found | Holds WHO-GMP and EU GMP certifications. |
| CLAROID PHARMACEUTICALS PRIVATE LIMITED | Not Listed | Yes | Not Found | Not Found | WHO-GMP certified as of July 24, 2025. |
TransData Nexus reviewed the regulatory standing of 2 leading Linagliptin exporters from India. 0 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 1 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Linagliptin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for active pharmaceutical ingredient (API) manufacturing. The city's well-established infrastructure, coupled with a skilled workforce and supportive government policies, has attracted numerous pharmaceutical companies specializing in API production. While specific data on Linagliptin production in Hyderabad is limited, the city's prominence in API manufacturing suggests a potential role in its production.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations industry. Companies in this region focus on producing finished dosage forms, including tablets and capsules. Intas Pharmaceuticals, headquartered in Ahmedabad, is a notable player in this sector. Although specific information on Linagliptin formulations by Intas is not available, the company's extensive portfolio and manufacturing capabilities indicate potential involvement in its production.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products. The region's proximity to major ports facilitates efficient international distribution. Pharmaceutical companies in this area leverage the logistical advantages to export APIs and finished formulations globally. While specific data on Linagliptin exports from this region is not detailed, the area's infrastructure supports significant export activities.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is a prominent pharmaceutical manufacturing zone, benefiting from tax incentives and a conducive business environment. BETA DRUGS LIMITED, the leading exporter of Linagliptin, is headquartered in Panchkula, Haryana, with manufacturing facilities in Baddi. The company's significant contribution to Linagliptin exports underscores the region's importance in pharmaceutical production.
5Sourcing Recommendations
- Diversify Supplier Base: While BETA DRUGS LIMITED dominates Linagliptin exports, engaging with other suppliers such as GANPATI EXIM INC and SHREE SSD PHARMA PRIVATE LIMITED can mitigate supply chain risks.
- Evaluate Manufacturing Capabilities: Assess the production capacities and quality standards of suppliers in key pharmaceutical clusters, including Hyderabad and Ahmedabad-Vadodara, to ensure consistent supply.
- Leverage Export Infrastructure: Utilize the logistical advantages of the Mumbai-Thane-Raigad region to streamline international distribution and reduce lead times.
- Monitor Regulatory Compliance: Ensure that selected suppliers adhere to international regulatory standards, facilitating smoother market entry and reducing compliance-related issues.
By strategically engaging with suppliers across India's pharmaceutical clusters and leveraging regional strengths, companies can optimize their Linagliptin sourcing strategies.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Linagliptin exporters from India
Akums Drugs and Pharmaceuticals Ltd. — Akums acquires Ankur Drugs' manufacturing units
Akums Drugs and Pharmaceuticals Ltd. completed the acquisition of manufacturing facilities from Ankur Drugs and Pharmaceuticals Limited. This strategic move aims to enhance Akums' production capabilities and expand its market presence. IMPACT: This acquisition may influence Linagliptin export dynamics by potentially increasing production capacity and competitive positioning.
Impact: This acquisition may influence Linagliptin export dynamics by potentially increasing production capacity and competitive positioning.
Unspecified — Kilitch Drugs (India) Limited acquisition announced
An acquisition involving Kilitch Drugs (India) Limited was announced, indicating potential consolidation within the pharmaceutical sector. Specific details regarding the acquiring entity and terms were not disclosed. IMPACT: The acquisition could affect Linagliptin exports depending on the strategic direction taken by the new ownership.
Impact: The acquisition could affect Linagliptin exports depending on the strategic direction taken by the new ownership.
GlaxoSmithKline plc — GlaxoSmithKline to acquire Sierra Oncology for $1.49 billion
GlaxoSmithKline plc announced the acquisition of Sierra Oncology, Inc., a move aimed at strengthening its oncology portfolio. The transaction is valued at approximately $1.49 billion. IMPACT: While primarily focused on oncology, this acquisition may indirectly influence Linagliptin exports through changes in market dynamics and resource allocation.
Impact: While primarily focused on oncology, this acquisition may indirectly influence Linagliptin exports through changes in market dynamics and resource allocation.
Common Questions — Linagliptin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which linagliptin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, BETA DRUGS LIMITED leads with 124 recorded shipments worth $2.5M. GANPATI EXIM INC (20 shipments) and SHREE SSD PHARMA PRIVATE LIMITED (16 shipments) are also established high-volume exporters.
Q How many linagliptin manufacturers are there in India?
India has 118 active linagliptin exporters with a combined export market of $3.9M across 1,375 shipments to 61 countries. The top 5 suppliers hold 76.3% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for linagliptin from India?
Average FOB unit price: $27.17 per unit, ranging from $0.01 to $2385.65. Average shipment value: $2.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 118 verified Indian exporters of Linagliptin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,375 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 61 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,375 Verified Shipments
118 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists